Login / Signup

NCAPH drives breast cancer progression and identifies a gene signature that predicts luminal a tumour recurrence.

Marina Mendiburu-EliçabeNatalia García-SanchaRoberto Corchado-CobosAngélica Martínez-LópezHang ChangJian-Hua MaoAdrián Blanco-GómezAna García-CasasAndrés Castellanos-MartínNélida SalvadorAlejandro Jiménez-NavasManuel Jesús Pérez-BaenaManuel Adolfo Sánchez-MartínMaría Del Mar Abad-HernándezSofía Del CarmenJuncal Claros-AmpueroJuan Jesús Cruz-HernándezCésar Augusto Rodríguez-SánchezMaría Begoña García-CenadorFrancisco Javier García-CriadoRodrigo Santamaría VicenteSonia Castillo-LluvaJesús Pérez Losada
Published in: Clinical and translational medicine (2024)
The GSLA10 signature outperformed the Oncotype DX signature in discerning tumours with unfavourable outcomes, previously categorised as luminal A by Prediction Analysis of Microarray 50 (PAM50) across three independent human cohorts. This new signature holds promise for identifying luminal A tumour patients with adverse prognosis, aiding in the development of personalised treatment strategies to significantly improve patient outcomes.
Keyphrases
  • genome wide
  • endothelial cells
  • emergency department
  • type diabetes
  • machine learning
  • gene expression
  • induced pluripotent stem cells
  • transcription factor
  • deep learning
  • electronic health record